Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects
暂无分享,去创建一个
[1] J. Pérez-Ruixo,et al. Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG‐TPOm) After Single Intravenous Dose Administration in Healthy Subjects , 2009, Journal of clinical pharmacology.
[2] Wojciech Krzyzanski,et al. Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition , 2007, The AAPS Journal.
[3] W. Krzyzanski,et al. Pharmacokinetic model of target-mediated disposition of thrombopoietin , 2004, AAPS PharmSci.
[4] J. Pérez-Ruixo,et al. Pharmacodynamic Analysis of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects , 2008, Clinical pharmacokinetics.
[5] Gisela Schwab,et al. Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in Healthy Subjects , 2006, Journal of clinical pharmacology.
[6] D. Mager,et al. Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2005, Pharmaceutical Research.
[7] J. T. Sullivan,et al. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand , 2004, Clinical pharmacology and therapeutics.
[8] Lewis B. Sheiner,et al. Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[9] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[10] R. Ramakrishnan,et al. Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[11] Hartmut Derendorf,et al. Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.
[12] N. Holford. Drug Concentration, Binding, and Effect In Vivo , 1984, Pharmaceutical Research.
[13] Yong Ho Kim,et al. Model Appropriateness and Population Pharmacokinetic Modeling , 2003, Journal of clinical pharmacology.
[14] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[15] C. Begley,et al. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. , 2002, Blood.
[16] C. Begley,et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. , 2002, Blood.
[17] Hannah M Linden,et al. Thrombopoietin: a pan-hematopoietic cytokine. , 2002, Cytokine & growth factor reviews.
[18] C. Yang,et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. , 2001, Blood.
[19] L. Harker,et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. , 2000, Blood.
[20] D. Kuter,et al. Interaction of thrombopoietin with the platelet c‐mpl receptor in plasma: binding, internalization, stability and pharmacokinetics , 1999, British journal of haematology.
[21] H. Avraham,et al. Binding and regulation of thrombopoietin to human megakaryocytes , 1998, British journal of haematology.
[22] J. Dempsey,et al. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells. , 1998, Blood.
[23] P. Hass,et al. Human platelets as a model for the binding and degradation of thrombopoietin. , 1997, Blood.
[24] V. Broudy,et al. Human platelets display high-affinity receptors for thrombopoietin. , 1997, Blood.
[25] J. Erusalimsky,et al. Megakaryocytopoiesis: The Megakaryocyte/Platelet Haemostatic Axis , 1997 .
[26] W. Sheridan,et al. Thrombopoiesis and Thrombopoietins Molecular, Cellular, Preclinical, and Clinical Biology , 1997 .
[27] B. Chong,et al. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. , 1997, Blood.
[28] K. Authi,et al. Platelets and Their Factors , 1997, Handbook of Experimental Pharmacology.
[29] R. Rosenberg,et al. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. , 1995, Blood.
[30] G Levy,et al. Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.
[31] R P STEPHENSON,et al. A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.